Patents by Inventor Hisanaka Ito

Hisanaka Ito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Agent or Prophylactic Agent for COVID-19
    Publication number: 20240024266
    Abstract: [Problem] To develop novel therapeutic agents for viral diseases such as coronavirus infections. [Solution] The present invention provides a therapeutic or prophylactic agent for viral diseases containing a compound with inhibitory activity against the function of Pin1 or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: November 16, 2021
    Publication date: January 25, 2024
    Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Takemasa Sakaguchi, Takeshi Yamamotoya, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe, Jeffrey Encinas
  • Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same
    Publication number: 20230133581
    Abstract: [Problem] To develop a group of novel compounds with an inhibitory activity against the function of Pin1 so as to use them as candidate compounds for medicaments.
    Type: Application
    Filed: March 9, 2021
    Publication date: May 4, 2023
    Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
    Patent number: 11504379
    Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 22, 2022
    Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used
    Patent number: 11203565
    Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: December 21, 2021
    Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity
    Patent number: 11071738
    Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: July 27, 2021
    Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same
    Publication number: 20200383967
    Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 10, 2020
    Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Novel Amide Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same
    Publication number: 20200383987
    Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 10, 2020
    Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Therapeutic Agent for Fatty Liver Diseases and Therapeutic Agent for Adiposity
    Publication number: 20200383989
    Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 10, 2020
    Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED
    Publication number: 20190382330
    Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.
    Type: Application
    Filed: November 29, 2017
    Publication date: December 19, 2019
    Applicants: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Catalytic compositions and methods for asymmetric aldol reactions
    Patent number: 6919456
    Abstract: Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula I, as defined further herein.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: July 19, 2005
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Barry M. Trost, Hisanaka Ito
  • Catalytic compositions and methods for asymmetric aldol reactions
    Publication number: 20040019239
    Abstract: Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula I, as defined further herein.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 29, 2004
    Inventors: Barry M. Trost, Hisanaka Ito
  • Catalytic compositions and methods for asymmetric aldol reactions
    Patent number: 6610889
    Abstract: Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula I, as defined further herein.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: August 26, 2003
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Barry M. Trost, Hisanaka Ito
  • Catalytic compositions and methods for asymmetric aldol reactions
    Publication number: 20020147367
    Abstract: Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula I, as defined further herein.
    Type: Application
    Filed: October 31, 2001
    Publication date: October 10, 2002
    Inventors: Barry M. Trost, Hisanaka Ito